CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx (CDNA) reported a director equity award. On 10/22/2025, the reporting person acquired 27,453 shares of Common Stock, labeled as an acquisition at a price of $0.
The award is represented by restricted stock units (RSUs) that vest in equal annual installments, with 100% vested on the third anniversary of October 22, 2025, subject to continued service. Each RSU represents the right to receive 1 share of Common Stock upon settlement for no consideration. Following the reported transaction, the reporting person beneficially owned 27,453 shares directly.
CareDx, Inc. (CDNA) reported an insider update: a company director filed a Form 3 initial statement of beneficial ownership. The filing states that no securities are beneficially owned by the reporting person.
The event date is 10/22/2025, and the form indicates it is filed by one reporting person. This is an administrative disclosure of insider status rather than a transaction.
CareDx (CDNA) appointed Suresh Gunasekaran as a Class II director, effective October 22, 2025. He is the CEO and President of UCSF Health and brings extensive health system leadership experience. The Board has not yet determined any committee assignments.
As a non-employee director, he will receive an annual cash retainer of $50,000, payable quarterly and electable in cash and/or common stock. He will receive an initial restricted stock unit grant with a grant date fair value of $400,000 that vests in three equal annual installments starting one year from appointment. Following each annual meeting, he will be automatically granted RSUs with a grant date fair value of $225,000, vesting on the earlier of one year from grant or immediately before the next annual meeting. The company executed its standard director indemnification agreement. No family relationships or related-party transactions were disclosed.
CareDx, Inc. (CDNA) reported an automatic non-employee director equity grant. On 10/06/2025 the reporting person received 1,753 shares of common stock as an automatic quarterly grant in lieu of cash under the companys Outside Director Compensation Policy. The reported price for the grant is $0, and the reporting persons total beneficial ownership after the grant is 155,969 shares. The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Insider transaction by CareDx, Inc. (CDNA) — Jessica Meng, the company’s Chief Commercial Officer, reported a disposition of 4,703 shares of CareDx common stock on 09/12/2025 at a price of $13.53 per share. After the transaction she beneficially owned 109,629 shares. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/15/2025.
CareDx insider grant reported: Nathan Smith, identified as Chief Financial Officer, acquired 42,000 restricted stock units (RSUs) on 08/07/2025, increasing his direct beneficial ownership to 42,000 shares. Each RSU is a contingent right to receive one share of the company's common stock upon settlement for no consideration. The RSUs vest over time: 25% of the total vests on August 7, 2026, with 1/16th of the total vesting in quarterly installments thereafter until fully vested, subject to continued service. No derivative securities were reported in Table II.
CareDx, Inc. filed an initial insider ownership report for its Chief Financial Officer, Nathan Smith. The filing states that he currently has no beneficial ownership of either non-derivative or derivative securities of CareDx. This means the CFO reports holding no company shares or related equity instruments in his name or through indirect arrangements.